Streptococcus suis and Streptococcus equi subsp. zooepidemicus are capable of infecting humans and various animals, causing significant problems for the worldwide swine industry. As antibiotic resistance has increased, lysosomal enzymes encoded by phages have shown potential for use against pathogenic bacteria. In this study, a novel bacteriophage lysin, Ply30, encoded by the S. suis prophage phi30c, was recombinantly expressed and purified. Ply30 showed high bacteriolysis activity on S. suis and S. equi subsp. zooepidemicus in vitro. The ratio of the optical density at 600 nm (OD 600 ) with treatment versus the OD 600 with no treatment for most tested S. suis and S. equi subsp. zooepidemicus strains decreased from 1 to <0.3 and <0.5, respectively, within 1 h. The results of plate viability assays showed that treated bacteria suffered a 1-to 2-log decrease in CFU within 1 h. The optimal concentration of Ply30 was 50 g/ml, and the optimal pH was 7. Moreover, Ply30 maintained high activity over a wide pH range (pH 6 to 10). The MICs of Ply30 against Streptococcus strains ranged from 16 to 512 g/ml. In vivo, a 2-mg dose of Ply30 protected 90% (9/10 mice) of mice from infection with S. equi subsp. zooepidemicus and 80% (8/10 mice) of mice from infection with S. suis. Seven days after lysin Ply30 treatment, bacterial loads were significantly decreased in all tested organs and blood compared with those at 1 h postinfection without Ply30 treatment. Ply30 showed in vitro and in vivo antimicrobial efficiency and protected mice against two kinds of bacterial infections, indicating that Ply30 may be an effective therapeutic against streptococci.
Actual inoculum titers for each experiment were determined by plate counting. For each strain, a PBS control or Ply30 at a final concentration of 50 g/ml was added to the samples. The mixtures were incubated at 37°C for 1 h, with agitation every 10 min. The cells were then serially 10-fold diluted and plated on THB agar. The viability of the bacteria was calculated as the decrease in the log CFU (24) .
Ply30 therapeutic trials in mice.
To test the protective effect of Ply30 against bacterial infections in mice, 20 4-week-old Institute for Cancer Research (ICR) female mice were inoculated intraperitoneally (i.p.) with 1 ϫ 10 5 CFU of S. equi subsp. zooepidemicus CVCC35246. Mice were divided into two groups at 1 h postinjection. One group (treated group) was treated with 2 mg of Ply30 in 0.2 ml i.p., while the other group (control group) received 0.2 ml of PBS i.p. in parallel. For therapeutic experiments with S. suis, 20 4-week-old BALB/c female mice were treated in the same way as that described above, except that strain CVCC35246 was replaced by 2.5 ϫ 10 8 CFU S. suis HA9801. Challenged mice were observed for 7 days postinfection, and survival curves were drawn and analyzed with the log rank (Mantel-Cox) and Gehan-Breslow-Wilcoxon tests, using GraphPad Prism 5.0. This experiment was performed in triplicate.
The bacterial loads of mice in vivo at 1 h postinfection or after treatment with Ply30 were determined. Six 4-week-old BALB/c female mice were infected with 2.5 ϫ 10 8 CFU S. suis HA9801. At 1 h postinfection, mice were divided into two groups. Group 1 was sacrificed by cervical dislocation, and various organs (brain, kidney, and lung; 1 g of each organ) and blood (1 ml) were homogenized with sterile PBS. Group 2 was treated with 2 mg of Ply30. After 7 days, the various organs and blood of group 2 were homogenized with sterile PBS, and the bacterial loads in these organs and blood were calculated by plate counting. Bacterial loads in various organs of mice infected with S. equi subsp. zooepidemicus CVCC35246 and treated with Ply30 were determined using the same method as that described above. MIC of Ply30. The MIC of Ply30 was determined in a 96-well plate as described by Lood et al. (31) . Briefly, 5.0 ϫ 10 5 CFU/ml of freshly cultured S. suis or S. equi subsp. zooepidemicus cells was added to each well. Ply30 was then added to different wells, with final concentrations ranging from 512 to 0.5 g/ml by double dilutions. The MIC value was tested after 16 h of incubation.
Ethics statement. The animal experiments were conducted with the permission of the Ministry of Science and Technology of Jiangsu Province. The license number is SYXK (SU) 2010-0005. All efforts were made to minimize suffering.
RESULTS
Cloning, expression, and purification of Ply30. The recombinant plasmid PET-32a(ϩ)_Ply30 was constructed, and the sequence of the Ply30-encoding gene within the plasmid was confirmed to be correct by sequencing. The recombinant phage lysin was purified by use of a HisTrap FF column, resulting in a band of approximately 46.8 kDa on SDS-PAGE (Fig. 1) . Ply30 was predicted to be a protein with a CHAP domain and an SH3 type 5 domain, as predicted by Pfam (32) .
Activity spectrum of Ply30. To test the activity spectrum of Ply30, inhibition of the growth of various bacterial strains was detected by a spot assay. Inhibition zones appeared on spot assay plates for 47 S. suis strains, indicating that 47 S. suis strains could be lysed by Ply30. Only three S. suis strains could not be lysed. The Ply30-encoding gene was harbored in the genome of S. suis serotype 9 strain 8067; however, the lytic spectrum of Ply30 was extensive, including S. suis serotypes 1, 2, 1/2, 4, 7, 9, 10, 11, 12, and 24 (Table 1 ). Moreover, six tested S. equi subsp. zooepidemicus strains and one S. uberis strain could also be lysed by Ply30. S. agalactiae, E. coli, and S. aureus could not be lysed. Among the three S. suis strains that could not be lysed, one strain (strain 55) belonged to S. suis serotype 9.
Optimal pH and concentration of Ply30. The optimal pH of . Cells with an initial OD 600 of 1 were then exposed to Ply30 (at the optimal concentration), and the decrease in OD 600 was monitored after 15 min, 30 min, and 1 h. The OD 600 of the cells showed the largest decrease at every time point when the pH was 7.
Ply30 was tested by the decrease in OD 600 of S. suis NJ-2 cells treated with Ply30 at different pHs. Ply30 showed low activity at pH 4 and 5 but high activity over a wide pH range (pH 6 to 10) (Fig. 2B) . At pH 7, the OD 600 value for S. suis decreased the most at all tested time points. The results revealed that Ply30 is sensitive to acid and tolerant to alkali and has an optimal pH of 7. S. suis NJ-2 cells were resuspended in PBS and adjusted to an OD 600 of 1. The decreases in turbidity of S. suis NJ-2 cells treated with different concentrations of Ply30 were observed at three time points: 15 min, 30 min, and 1 h. Generally, Ply30 exhibited a reasonably fast bacteriolytic effect. S. suis NJ-2 cells had decreased OD 600 ratios (to Ͻ0.3) at all concentrations of Ply30 (except 10 g/ml) within 15 min (Fig. 2A) . The bacteriolytic effects of 50 g/ml Ply30 were very close to the effects of 100 g/ml Ply30; thus, we chose 50 g/ml as the optimal final concentration of Ply30. Spectrophotometric lysis assays. Purified Ply30 was tested against different species of bacteria to determine the range of lytic activity. Ply30 showed stronger lytic activity against S. suis (including different serotypes) than against S. equi subsp. zooepidemicus and S. uberis (Fig. 3) . The OD 600 ratio for most S. suis strains dropped to Ͻ0.2. Ply30 could even lyse a novel serotype of S. suis, strain CZ130302 (33) . The OD 600 ratios for S. equi subsp. zooepidemicus and S. uberis were reduced to Ͻ0.5 and Ͻ0.4, respectively. Ply30 did not reduce the OD 600 ratio for any tested S. agalactiae, S. aureus, and E. coli strains.
Plate viability assays. To further detect the lytic effect of Ply30, the viabilities of 10 S. suis strains, 1 S. equi subsp. zooepidemicus strain, and 1 S. uberis strain were calculated by plate counting. The initial concentration of bacteria was 1 ϫ 10 7 to 5 ϫ 10 7 CFU/ml. After treatment with 50 g/ml (final concentration) of Ply30 for 1 h, most S. suis strains (except for m70 and CZ130302) achieved an ϳ2-log decrease in CFU (Fig. 4) . The viabilities of three strongly virulent S. suis serotype 2 strains (BAA853, ZY05719, and HA9801) decreased the most. S. equi subsp. zooepidemicus decreased by ϳ1 log CFU, while S. uberis decreased Ͻ1 log CFU.
Ply30 therapeutic trials in mice.
Mice were i.p. injected with 10 5 CFU of S. equi subsp. zooepidemicus CVCC335246 or 2.5 ϫ 10 8 CFU of S. suis HA9801 and treated with either 2 mg Ply30 (10 mice) or PBS (10 mice) 1 h later. The ten mice of the control group were dead within 96 h, while 90% (9/10 mice) of mice infected with CVCC335246 and treated with Ply30 and 80% (8/10 mice) of mice infected with HA9801 and treated with Ply30 remained alive. Figure 5 shows that Ply30 improved survival within 96 h for the treatment groups. The survival rates of the treatment groups and untreated controls showed statistically significant differences (P Ͻ 0.01).
The bacterial loads in different organs and blood were monitored at 1 h postinfection and 7 days after treatment with Ply30. S. suis and S. equi subsp. zooepidemicus were both distributed at high concentrations in different organs and in blood at 1 h postinfection. At 1 h postinfection, the bacterial loads of S. suis reached 10 6 to 10 7 CFU/ml in different organs. Meanwhile, the bacterial loads decreased by 3 to 5 log after 7 days of treatment with Ply30 (Fig. 6) . The bacterial loads of S. equi subsp. zooepidemicus reached 10 2 to 10 4 CFU/ml in different organs at 1 h postinjection. However, 7 days after treatment with Ply30, bacteria could hardly be detected in all tested organs (Fig. 7) .
MICs of Ply30. The MICs of Ply30 against S. suis or S. equi subsp. zooepidemicus strains ranged from 16 to 512 g/ml (Table  2 ). Corresponding to the results of the lytic assays, the MICs of Ply30 against S. suis strains were generally lower than those against S. equi subsp. zooepidemicus strains. As a negative control, the Ply30 MIC of E. coli CVCC1506 was Ͼ512 g/ml.
DISCUSSION
Besides some drawbacks, such as producing antibodies in vivo and production costs, phage lysins have the following advantages over antibiotics: low probability of resistance, large in vitro and in vivo effects against bacteria, and wide availability from phages (34) (35) (36) . S. suis lytic phages are difficult to isolate. Until now, only one S. suis lytic phage, SMP, was reported (23, 37) . Thus, phage lysins were expected to prevent S. suis infections. Numerous effective lysins derived from various species (Streptococcus pneumoniae, S. pyogenes, S. agalactiae, Staphylococcus, etc.) have been reported in recent years (30, 31, (38) (39) (40) . However, only three S. suis phage lysins (PlySs1, PlySs2, and LySMP) have been reported (24, 26, 27) . Ply30 shows no amino acid similarity to these S. suis phage lysins. Among the three S. suis phage lysins, LySMP has high homology to PlySs1 and has low enzymatic activity, showing enzy- (24) . However, the two lysins protect different species from infections in vivo: PlySs2 protects mice against S. pyogenes and MRSA infections (24) , while Ply30 protects them against S. suis and S. equi subsp. zooepidemicus infections. Thus, these lysins have different possible applications in the prevention of bacterial infection.
Therapeutic trials in mice were performed to test the activity of Ply30 in vivo. Mice were treated with Ply30 at 1 h postinfection because the bacteria reached high concentrations in various organs and blood within 1 h (Fig. 6 and 7) . Ply30 protected 90% of mice infected with S. equi subsp. zooepidemicus. The survival rates of the treated and control groups were significantly different (P Ͻ 0.01), which suggested that Ply30 has a high protective ability against S. equi subsp. zooepidemicus infection. For S. suis, 80% of mice in the treated group were protected by Ply30, which was significantly different from the results for the control group (P Ͻ 0.01). The protective effect of Ply30 against S. suis infection was not as large as that against S. equi subsp. zooepidemicus infection in vivo, although Ply30 showed a higher bacteriolysis activity on S. suis than on S. equi subsp. zooepidemicus in vitro. This might reflect the different pathogenicities of S. suis and S. equi subsp. zooepidemicus in mice.
To investigate the processes of infection and protection in vivo, the bacterial loads of different organs and blood were monitored. The results showed that 7 days after treatment with the Ply30 lysin, the bacterial loads had decreased 3 to 5 log (P Ͻ 0.01) in all organs and blood tested for S. suis (Fig. 6 ). For S. equi subsp. zooepidemicus, bacteria in different organs and blood were almost completely eliminated 7 days after treatment with the Ply30 lysin (Fig. 7) . It is interesting that Ply30 showed higher bacteriolysis activity on Streptococcus in vivo than in vitro, indicating that the phage lysin might work in different ways in vivo and in vitro. One theory is that the phage lysin might have synergistic effects on the immune system of the host, resulting in better elimination of pathogens. The results demonstrated that Ply30 could protect mice against two kinds of bacterial infection. To the best of our knowledge, only the S. suis prophage lysin PlySs2 could protect mice against infection by more than one species of bacteria (24) . Two S. suis phage lysins and one S. equi subsp. zooepidemicus phage lysin have been reported; however, except for the S. suis prophage lysin PlySs2, the others were not confirmed to protect animals against more than one kind of bacterial infection (24, 26, 41) , indicating that phage lysins that have high activity in vitro might not be effective in vivo. The strain HA9801 (S. suis type 2) was isolated from a pig with septicemia in Jiangsu Province, China, in 1998 (42), and S. equi subsp. zooepidemicus ATCC 35246 was isolated from a dead pig with septicemia in Sichuan Province, China (43) . Both strains are strongly virulent strains that can infect pigs (43, 44) , indicating that Ply30 has the potential to protect against infections by these two bacteria. The activities of lysins against a species are usually higher than that of the parental phage (24) . Ply30 showed a broad lytic spectrum in two species of bacteria and could lyse a wide range of serotypes within S. suis strains. Phage lysins from a Gram-positive background have cell wall binding domains (CBDs), which are involved in substrate recognition, and enzymatically active domains (EADs), which have catalytic activity (45, 46) . Lysin specificity is determined by phage lysin binding domains (47) . The SH3b (bacterial SH3-like) domain of staphylococcal lysin was one of the earliest identified sequences with a cell wall binding function (48) . The interpeptide pentaglycine bridges within the S. aureus peptidoglycan were targeted by the SH3b domain of ALE-1 (49) . This amine might be the target of the Ply30 SH3 domain in the cell wall structures of Gram-positive bacteria. Accordingly, further experiments are required to demonstrate the binding substrates of Ply30. Interestingly, Ply30 showed lytic activity against all tested serotype 9 strains except strain 55. This phenomenon was noted previously (26): the S. suis phage lysin LySMP could lyse most S. suis strains, except for two S. suis serotype 2 strains: 006731 and SS2-9. We presume that their receptors that interact with lysins might be different from those of the other strains. Ply30 has a certain effect on eliminating pathogenic bacteria: the OD 600 ratio for bacteria decreased to Ͻ0.3, or even Ͻ0.2, within 15 min. Its working concentration is only 50 g/ml. Actually, 20 g/ml Ply30 could decrease the bacterial OD 600 ratio to Ͻ0.3 within 15 min (Fig. 2A) . Additionally, recombinant Ply30 yielded a high level of product and was tolerant to a wide pH range. Thus, Ply30 has the potential to be an antibacterial agent.
